Infec Dis Drug/Vacc Ed

Abstract

This Project funds development of candidate medical countermeasures (MCM: e.g., vaccines, drugs, diagnostic kits/devices) for militarily relevant endemic infectious diseases. It funds research that supports conclusive human clinical trials to demonstrate MCM effectiveness safety and related manufacturing tests. This work, which is jointly performed by military laboratories, civilian contracted pharmaceutical firms and foreign research partners, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. Medical products approved for human use must meet the United States (U.S.) Food and Drug Administration (FDA) approval before MCM can be used on Warfighters. Development priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands' theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development, production, and sustainment). Malaria, dysentery and dengue diseases (a severe debilitating disease transmitted by mosquitoes), which are found in all Combatant Command areas and are at the top of the infectious diseases risks list.

Open PDF

Document Details

Document Type
Project
Publication Date
Oct 01, 2024
Source ID
849_0604807A_5_2040_PB_2024

Tags

Fields of Study

  • Medicine

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Infectious Disease/Epidemiology
  • Military Science and Technology Research and Modernization.

Technology Areas

  • Biotechnology

Related Documents